Steven Brem, MD, Professor of Neurosurgery, Chief of the Division of Neurosurgical Oncology and Co-Director of the Penn Brain Tumor Center, has received the first Joel A. Gingras, Jr. award given by the American Brain Tumor Association (ABTA).
Dr. Brem has performed more than 3,600 brain tumor surgeries, participated in over 100 clinical trials and has conducted extensive research in the discovery and translation of novel inhibitors of angiogenesis and glioma progression. The Penn Brain Tumor Center brings together clinicians and scientists from across Penn Medicine, including Penn Neurosurgery and Penn’s Abramson Cancer Center.
The Joel A. Gingras, Jr. award, launched by the ABTA's Board of Directors in 2010, acknowledges exceptional organizations or individuals making a noteworthy impact on furthering the ABTA’s mission to advance the understanding and treatment of brain tumors. Read more here.
The Penn Brain Tumor Center (BTC) is nationally recognized for innovative, cutting-edge therapy of benign and malignant tumors originating in the brain, as well as metastatic cancer that originates outside of the brain. A collaborative team of Penn specialists work to develop a customized, personalized treatment plan based on a comprehensive, multidisciplinary review of all of the diagnostic information available. This includes molecular profiling, advanced neuroimaging and neurocognitive testing to select the best therapeutic options. The BTC is dedicated to a single mission: from discovery to recovery, the Penn Brain Tumor Center provides a circle of exceptional care for patients with brain tumors.